Probupine contains a medication that in oral form has become a popular tool for eliminating opioid withdrawal symptoms. » Read More
Titan Pharmaceuticals Inc and privately owned Braeburn Pharmaceuticals have together developed a matchstick-sized implant that analysts expect will be approved next month, despite mixed reviews. The market for the implant could also be much bigger than first envisaged should a bill gaining bipartisan support on Capitol Hill become law.
Mark Bertolini, Aetna Chairman & CEO, talks about the company's quarterly earnings, Obamacare exchanges and drug pricing.
The county sheriff investigating the death of Prince is asking for help from the Drug Enforcement Administration.
Smokers looking to quit tobacco should switch to e-cigarettes, despite the product's controversy, a U.K. medical body has advised.
Jim Cramer explains what to watch ahead of the open, including Sarepta's waiting game with the FDA, and the millennial credit card.
The 300 million pain prescriptions written last year equal a $24B market, but it's not a market evenly divided around the globe.
Americans consume about 80% of the world's opioids. That's created a big business, with serious societal side effects. CNBC’s Dina Gusovsky reports.
Ezekiel Emanuel, Chair of Medical Ethics & Health Policy at the University of Pennsylvania, and Darcy Olsen, Goldwater Institute President, discuss the ethical arguments around whether patients should have the right to try potentially risky medical trials and therapies.
Liisa Bayko, JMP Securities Biotech Analyst and Managing Director, discusses the FDA's rejection of fast-track approval of Sarepta's Duchenne muscular dystrophy drug.
Bristol-Myers Squibb CEO Giovanni Caforio, discusses cancer research and affordability of medicine.
Discussing the play on Sarepta Therapeutics as its Duchenne muscular dystrophy drug sees pressure from FDA, with the FMHR traders.
Wall Street turned bearish on FDA approval for the Duchenne muscular dystrophy drug, reports CNBC's Meg Tirrell.
The panel is not recommending FDA approval for a Sarepta Therapeutics drug.
Eli Lilly reports lower-than-expected earnings due largely to heavy spending on research.
Pharma company Valeant has been under fire recently, but this investor says it's a buy.
Large employers are losing $10 billion each year due to the explosion of opioid abuse in the US.
Angel investor Jason Calacanis says "this is the worst crisis PR" by Theranos CEO Elizabeth Holmes. Calacanis says "there is going to be a $9 billion crater" left by Theranos.
Merck CEO Kenneth Frazier talks with CNBC's Meg Tirrell about his company's avoidance of tax inversion deals, as well as his views on the M&A environment and drug pricing.
President Obama takes on the prescription painkiller and heroin addiction epidemic ravaging the US. CNBC's Dina Gusovsky reports.
Discussing certain drugs becoming more and more expensive, and legislation to fix it, with Sen. Amy Klobuchar (D-Minn.).